Navigating the Evidence: Pathways for New and Emerging BCMA Therapies

Despite treatment advances, most patients with multiple myeloma will progress after administration to the standard of care regimens, including proteasome inhibitors, immunomodulatory agents, and chemotherapy. Therefore, it is important for the continual development of novel and effective therapies, especially for underserved communities. Agents targeting B-cell maturation antigen (BCMA) have shown substantial therapeutic responses. Join us in the 2nd episode of the 3-part Med Table Talk^® on Navigating the Evidence: Pathways for New and Emerging BCMA Therapies as our expert faculty discuss the safety and efficacy of the emerging BCMA agents. In addition, don’t miss out on the featured conversation with Dr. Saad Usmani, MD, as he discusses practical strategies to improve diversity in clinical trial enrollment.